Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
National Institute Of Transplantation
1972
mi
from 43215
Los Angeles, CA
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
National Institute Of Transplantation
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
California Institute of Renal Research
1947
mi
from 43215
San Diego, CA
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
California Institute of Renal Research
1947
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
UCSF
2108
mi
from 43215
San Francisco, CA
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
UCSF
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
University of Chicago
270
mi
from 43215
Chicago, IL
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
University of Chicago
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
Pharmacy, First Call Iv
799
mi
from 43215
Kenner, LA
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
Pharmacy, First Call Iv
799
mi
from 43215
Kenner, LA
Click here to add this to my saved trials
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
Tulane University Hospital & Clinic
798
mi
from 43215
New Orleans, LA
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
Tulane University Hospital & Clinic
798
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
University of North Carolina School of Medicine
354
mi
from 43215
Chapel Hill, NC
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
University of North Carolina School of Medicine
354
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated:  11/7/2016
Local Institution
5386
mi
from 43215
Capital Federal,
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Belatacept Conversion Trial in Renal Transplantation
Status: Enrolling
Updated: 11/7/2016
Local Institution
5386
mi
from 43215
Capital Federal,
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
2028
mi
from 43215
Roseville, CA
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
2028
mi
from 43215
Roseville, CA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
973
mi
from 43215
Cooper City, FL
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
973
mi
from 43215
Cooper City, FL
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
989
mi
from 43215
Miami Springs, FL
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
989
mi
from 43215
Miami Springs, FL
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
482
mi
from 43215
Bronx, NY
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
482
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
1
mi
from 43215
Columbus, OH
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
1
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
404
mi
from 43215
Bethlehem, PA
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
404
mi
from 43215
Bethlehem, PA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
362
mi
from 43215
Chattanooga, TN
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
362
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
864
mi
from 43215
Greenville, TX
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
864
mi
from 43215
Greenville, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
995
mi
from 43215
Houston, TX
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
1138
mi
from 43215
San Antonio, TX
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
A Phase 1, Open-label, Single Dose, Mass Balance Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of 14C-JTZ-951 in Male Subjects With End-stage Renal Disease Receiving Hemodialysis
Status: Enrolling
Updated:  11/28/2016
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
A Phase 1, Open-label, Single Dose, Mass Balance Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of 14C-JTZ-951 in Male Subjects With End-stage Renal Disease Receiving Hemodialysis
Status: Enrolling
Updated: 11/28/2016
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigative site
1982
mi
from 43215
Los Angeles, CA
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigative site
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigative site
1982
mi
from 43215
Los Angeles, CA
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigative site
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigative Site
537
mi
from 43215
New Haven, CT
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigative Site
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigator Site
277
mi
from 43215
Chicago, IL
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigator Site
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigator Site
277
mi
from 43215
Chicago, IL
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigator Site
277
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigative Site
395
mi
from 43215
St Louis, MO
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigative Site
395
mi
from 43215
St Louis, MO
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis
481
mi
from 43215
New York, NY
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigational Site
525
mi
from 43215
Charleston, SC
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigational Site
525
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigative Site
995
mi
from 43215
Houston, TX
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigative Site
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigative Site
1513
mi
from 43215
Salt Lake City, UT
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigative Site
1513
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigative site
395
mi
from 43215
Madison, WI
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigative site
395
mi
from 43215
Madison, WI
Click here to add this to my saved trials
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated:  11/29/2016
Novartis Investigative Site
9882
mi
from 43215
Parkville,
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
Status: Enrolling
Updated: 11/29/2016
Novartis Investigative Site
9882
mi
from 43215
Parkville,
Click here to add this to my saved trials
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
Oral Hydration and Alkalinization is Non-Inferior to Intravenous Therapy for Prevention of Contrast Induced Nephropathy in Patients With Chronic Kidney Disease.
Status: Enrolling
Updated:  11/29/2016
Western Pennsylvania Hospital
165
mi
from 43215
Pittsburgh, PA
Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy
Oral Hydration and Alkalinization is Non-Inferior to Intravenous Therapy for Prevention of Contrast Induced Nephropathy in Patients With Chronic Kidney Disease.
Status: Enrolling
Updated: 11/29/2016
Western Pennsylvania Hospital
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
Status: Enrolling
Updated:  11/30/2016
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
Status: Enrolling
Updated: 11/30/2016
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
1953
mi
from 43215
Coronado, CA
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
1953
mi
from 43215
Coronado, CA
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
1926
mi
from 43215
La Jolla, CA
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
1926
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
711
mi
from 43215
Gainesville, FL
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
711
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
993
mi
from 43215
Miami, FL
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
493
mi
from 43215
Manhasset, NY
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
493
mi
from 43215
Manhasset, NY
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
481
mi
from 43215
New York, NY
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
350
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
991
mi
from 43215
Houston, TX
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated:  12/7/2016
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)
Status: Enrolling
Updated: 12/7/2016
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials